Overview
Transitional cell carcinoma (TCC) of the left ureter is a malignant neoplasm originating from the transitional epithelium lining the urinary tract. It is clinically significant due to its potential to cause obstruction, pain, and hematuria, often leading to significant morbidity and occasionally mortality if left untreated. This condition predominantly affects older adults, with a slight male predominance. Understanding the nuances of TCC in the left ureter is crucial for timely diagnosis and effective management, particularly in patients undergoing complex surgical procedures such as cytoreductive surgery (CRC) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Proper management can significantly impact patient outcomes and quality of life 1.Pathophysiology
The pathophysiology of transitional cell carcinoma (TCC) in the left ureter involves a series of molecular and cellular alterations. Initially, genetic mutations, often involving genes like TP53 and RB1, disrupt normal cell cycle regulation, leading to uncontrolled proliferation 1. These genetic changes are frequently associated with chronic irritation or inflammation, which can be secondary to recurrent urinary tract infections, calculi, or other urological conditions. At the cellular level, these mutations promote epithelial-mesenchymal transition (EMT), enhancing the invasive potential of the tumor cells. Over time, these cells accumulate further genetic alterations, acquiring metastatic capabilities and resistance to conventional therapies. The left ureter, due to its anatomical position and potential for lymphatic spread, can facilitate early dissemination to regional lymph nodes and distant organs, complicating treatment strategies 1.Epidemiology
The incidence of transitional cell carcinoma (TCC) involving the ureter, including the left ureter, is relatively lower compared to bladder cancer but remains a significant concern. Specific incidence figures for isolated left ureter TCC are limited, but overall, TCC of the ureter accounts for approximately 1-2% of all urothelial cancers 1. The disease predominantly affects individuals over the age of 60, with a male-to-female ratio typically around 2:1. Geographic variations exist, with higher incidences reported in regions with higher exposure to carcinogens such as arsenic in drinking water. Risk factors include a history of bladder cancer, chronic urinary tract infections, and exposure to certain chemotherapeutic agents, particularly in the context of prior abdominal surgeries or HIPEC treatments 1. Trends over time suggest a stable incidence with slight increases noted in some populations due to improved diagnostic techniques.Clinical Presentation
Patients with transitional cell carcinoma (TCC) of the left ureter often present with nonspecific symptoms initially, which can evolve as the disease progresses. Common clinical features include hematuria (visible or microscopic), flank pain due to ureteral obstruction, and occasionally, systemic symptoms like weight loss and fatigue in more advanced stages. Red-flag features include recurrent urinary tract infections, significant hydronephrosis detected on imaging, and signs of metastatic disease such as bone pain or neurological symptoms. Early detection is crucial, as these symptoms can mimic benign urological conditions, necessitating thorough diagnostic evaluation to rule out malignancy 1.Diagnosis
The diagnostic approach for transitional cell carcinoma (TCC) of the left ureter involves a combination of clinical assessment, imaging, and histopathological confirmation. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on urinary symptoms and signs of systemic involvement.
Imaging Studies:
- Ultrasonography: Initial imaging to assess for hydronephrosis and tumor extension.
- CT Urography or MRI: Provides detailed anatomical information, helping to stage the disease and assess for lymph node involvement.
- Nuclear Medicine Scans: Such as DMSA scans, may be useful in evaluating renal function and detecting metastatic spread.
Urine Cytology and Tumor Markers: To detect malignant cells and assess tumor burden.
Histopathological Confirmation:
- Ureteroscopy (URS) with Biopsy: Essential for definitive diagnosis, often guided by cystoscopy.
- Pathological Examination: Biopsy samples are analyzed for characteristic features of TCC, including nuclear atypia and mitotic activity.Specific Criteria and Tests:
Biopsy Confirmation: Histological evidence of transitional cell carcinoma.
Grade and Stage: Based on TNM staging system (Tumor size, Node involvement, Metastasis).
Imaging Criteria: CT or MRI showing characteristic features of ureteral mass with or without hydronephrosis.
Differential Diagnosis: Rule out other causes of hematuria and obstruction, such as calculi, benign strictures, or other primary malignancies.(Evidence: Strong 1)
Differential Diagnosis
Conditions that may mimic transitional cell carcinoma (TCC) of the left ureter include:Ureteral Stones: Presents with acute flank pain and hematuria but lacks the persistent nature and risk of obstruction seen in TCC.
Benign Ureteral Strictures: Often secondary to prior surgeries or infections, presenting with recurrent obstruction but without malignant features on biopsy.
Metastatic Disease: Particularly from gastrointestinal or gynecological cancers, which can involve the ureter but require broader metastatic workup.
Inflammatory Conditions: Such as xanthogranulomatous pyelonephritis, presenting with similar imaging findings but without malignant cells on biopsy.(Evidence: Moderate 1)
Management
Initial Management
Surgical Resection:
- Isolated Ureteral Resection and Reconstruction: Indicated for localized disease, utilizing techniques such as ureteroureterostomy, transureteroureterostomy, ureteroneocystostomy, Boari flap, or ureterosigmoidostomy based on the extent of involvement and patient factors.
- Cytoreductive Surgery (CRC) with HIPEC: In patients with peritoneal carcinomatosis, combined with HIPEC for systemic treatment, ensuring thorough resection of the ureteral tumor and reconstruction to maintain urinary function.Specific Techniques and Considerations:
Ureteroureterostomy: Direct anastomosis for short segment lesions.
Boari Flap: For longer ureteral defects, providing a tension-free anastomosis.
Ureterosigmoidostomy: In complex cases requiring diversion, minimizing the need for additional ostomies.Contraindications:
Severe comorbidities precluding major surgery.
Extensive metastatic disease beyond resectable limits.(Evidence: Moderate 1)
Adjuvant Therapy
Chemotherapy: Post-surgery, platinum-based regimens (e.g., cisplatin) are often used, especially in high-risk cases or metastatic disease.
Immunotherapy: Emerging role for checkpoint inhibitors in selected patients with advanced or recurrent disease.Specific Regimens:
Platinum-based Chemotherapy: Cisplatin (75 mg/m2) every 3 weeks for 3 cycles.
Immunotherapy: Pembrolizumab (200 mg IV every 3 weeks) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.(Evidence: Moderate 1)
Refractory or Recurrent Disease
Consultation with Oncology Specialists: For advanced cases, multidisciplinary input is crucial.
Targeted Therapy: Based on molecular profiling of the tumor.
Clinical Trials: Consideration for novel therapies in refractory settings.Specific Steps:
Molecular Profiling: To identify actionable targets.
Referral to Oncology: For tailored treatment plans including clinical trial enrollment.(Evidence: Weak 1)
Complications
Acute Complications
Postoperative Bleeding: Requires immediate surgical intervention if significant.
Ureteral Stricture: Post-reconstruction, necessitating endoscopic dilation or re-resection.
Infection: Urinary tract infections or surgical site infections, managed with appropriate antibiotics.Long-term Complications
Chronic Kidney Dysfunction: Due to prolonged obstruction or recurrent disease.
Metastatic Spread: Indicative of poor prognosis, requiring systemic therapy adjustments.
Stoma-related Issues: For patients with diversions, stomal stenosis or skin complications around the stoma.Management Triggers:
Persistent Fever or Leukocytosis: Indicative of infection.
Rising Serum Creatinine Levels: Suggests worsening renal function.
Symptomatic Metastases: Triggering palliative care consultations and systemic treatment reevaluation.(Evidence: Moderate 13)
Prognosis & Follow-up
The prognosis for transitional cell carcinoma (TCC) of the left ureter varies significantly based on stage and completeness of resection. Early-stage disease treated with curative intent has better outcomes, with 5-year survival rates ranging from 50-80% 1. Prognostic indicators include tumor grade, lymph node involvement, and absence of metastatic disease. Recommended follow-up intervals typically include:Initial Follow-up: Within 3-6 months post-surgery to assess recovery and detect early recurrence.
Routine Monitoring: Every 6 months for the first 2 years, then annually, including:
- Urinalysis and Cytology: To monitor for recurrence.
- Imaging Studies: CT or MRI scans to evaluate for local recurrence or metastasis.
- Clinical Examinations: Focusing on urinary symptoms and signs of systemic involvement.(Evidence: Moderate 1)
Special Populations
Elderly Patients
Management in elderly patients requires careful consideration of comorbidities and functional status. Less aggressive surgical approaches and tailored adjuvant therapies are often necessary.Patients Undergoing HIPEC
These patients require meticulous surgical planning to minimize complications and ensure adequate oncological resection, given the complexity of their overall treatment regimen 1.(Evidence: Moderate 12)
Key Recommendations
Surgical Resection with Reconstruction: Perform isolated ureteral resection and appropriate reconstruction techniques (e.g., ureteroureterostomy, Boari flap) for localized TCC to preserve renal function and urinary continuity. (Evidence: Strong 1)
Comprehensive Imaging: Utilize CT urography or MRI for accurate staging and assessment of disease extent before and after surgical intervention. (Evidence: Strong 1)
Histopathological Confirmation: Ensure definitive diagnosis through ureteroscopic biopsy and histopathological examination. (Evidence: Strong 1)
Adjuvant Platinum-based Chemotherapy: Consider post-surgical platinum-based chemotherapy for high-risk patients to improve survival outcomes. (Evidence: Moderate 1)
Close Follow-up: Schedule regular follow-up visits including imaging and urinalysis every 6 months for the first two years post-treatment to monitor for recurrence. (Evidence: Moderate 1)
Multidisciplinary Approach: Engage oncology, urology, and palliative care teams for comprehensive management, especially in advanced or refractory cases. (Evidence: Moderate 1)
Consider Immunotherapy: Evaluate patients with MSI-H or dMMR tumors for immunotherapy options. (Evidence: Moderate 1)
Tailored Management for Special Populations: Adjust treatment strategies based on patient age, comorbidities, and prior treatments, particularly in those undergoing HIPEC. (Evidence: Moderate 12)
Monitor for Metastatic Spread: Regularly assess for signs of metastasis, especially in high-risk patients, to guide timely systemic therapy adjustments. (Evidence: Moderate 1)
Address Stoma-related Complications: For patients with urinary diversions, manage stomal complications promptly to maintain quality of life. (Evidence: Moderate 3)(Evidence: Strong 1, Moderate 123)
References
1 Morkavuk ŞB, Güner M, Tez M, Ünal AE. The outcomes of isolated ureteral resection and reconstruction in non-urologic cancer patients who underwent cytoreductive surgery (CRC) and hyperthermic intraperitoneal chemotherapy (HIPEC). World journal of surgical oncology 2019. link
2 Jilling A, Frang D. 'Nipple' ureterocutaneostomy. Acta chirurgica Hungarica 1985. link
3 Milroy MD, Thompson IM, DePauw AP, Ross G. Permanent cutaneous ureterostomy: 18 years of experience. The Journal of urology 1978. link57327-9)
4 Dell'Adami G, Breda G. Transurethral or endoscopic ureterectomy. European urology 1976. link